Navigation Links
Avaxia Biologics Elects Christopher Kiritsy to its Board of Directors
Date:4/26/2012

LEXINGTON, Mass., April 26, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, announced today that it has elected Christopher Kiritsy, President and Chief Executive Officer of Arisaph Pharmaceuticals, Inc. to its Board of Directors.

"I am pleased that Chris has agreed to serve on our Board," said Dr. Barbara Fox, founder, CEO and a member of the Board of Avaxia.  "As we position the company for our next phase of growth that includes manufacturing clinical materials for our inflammatory bowel disease (IBD) program and initiating our Phase I clinical trial in IBD later this year, Christopher's broad experience in building young biotech companies, his strong insight into product development and his financial expertise will be invaluable."  

About Christopher Kiritsy:
Mr. Kiritsy is a co-founder and President and Chief Executive Officer of Arisaph Pharmaceuticals, Inc. and has served as a Director since inception.  Mr. Kiritsy is a seasoned entrepreneur, who possesses 20+ years of business and technical experience, previously holding senior management positions in R&D, business development and finance.  At Arisaph, Mr. Kiritsy has evolved the organization from an academic, research orientation to a clinical development enterprise with a rich research pipeline, which led to one of the highest awards from the U.S. government's Therapeutics Discovery Project Program totaling nearly $3 million with all 12 projects funded.  Additionally, Mr. Kiritsy has executed multiple business development transactions, leveraging Arisaph's strong IP to raise in excess of 70% of its total capital from non-dilutive sources.

Prior to Arisaph, Mr. Kiritsy served as Executive Vice President, Corporate Development and Chief Financial Officer of Kos Pharmace
'/>"/>

SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
2. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
3. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
4. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
5. CMC Biologics Highlights Technical Acumen at Upcoming Conferences
6. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimestaâ„¢ for Multiple Sclerosis
7. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
8. Adeona Becomes Synthetic Biologics, Inc.
9. Pinnacle Biologics, Inc. Announces the Successful Completion of a Financing Round
10. CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems
11. Bacterin Becomes Premier Founding Sponsor of RMECs New Osteobiologics Registry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... 1, 2015  Turing Pharmaceuticals AG announced that life ... , MD, MSc,  has joined the company as ... Salinas, who holds a medical degree as well ... of significant accomplishments in the pharmaceutical industry, and ... Salinas has played a leadership role in numerous ...
(Date:6/1/2015)... 1, 2015 GenomeDx Biosciences today ... platform, successfully classified various subtypes of bladder ... certain biomarkers, including one type associated with ... genomic signature has potential as a tool ... in patients with muscle-invasive bladder cancers (MIBC). ...
(Date:6/1/2015)... June 1, 2015 Research ... addition of the "Global PDT Machine Industry ...        (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... is a professional and in-depth study on the ... report provides a basic overview of the industry ...
(Date:6/1/2015)... , June 1, 2015  Fennec Pharmaceuticals, Inc. ... positive interim results from a poster presented today ... label randomised phase III trial of the efficacy ... patients receiving cisplatin (Cis) monotherapy for standard risk ... American Society of Clinical Oncology (ASCO) 2015 Annual ...
Breaking Biology Technology:Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Global PDT Machine Industry Report 2014 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4
... - Dr. Liew awarded Malaysia,s Darjah Yang Mulia ... - GeneNews Limited (TSX: GEN),a company focused on ... of diseases and personalized health management, today,announced that ... Liew,was awarded the Darjah Yang Mulia Pangkuan Negeri ...
... Imprint to Yield a Strong and ... Highly Specific Immune Response, ... ILNS) a biopharmaceutical company focused on,development of disease-modifying therapeutic agents ... announced today,that Dr. Rachel Eren, Vice President Research, will present ...
... Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT),announced that ... than,35% over the first quarter of 2007 exceeding $1,872,000 ... same period in the previous year. Revenues for ... only,$24,374 in the first half of 2006. These significant ...
Cached Biology Technology:GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia 2Intellect Neurosciences, Inc. to Present Data on Alzheimer's Vaccine at 13th International Congress of Immunology Conference 2Intellect Neurosciences, Inc. to Present Data on Alzheimer's Vaccine at 13th International Congress of Immunology Conference 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 4Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 5Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 6
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... for Secure and Resilient Maritime Commerce (CSR) at Stevens Institute ... Stevens was named by the US Department of Homeland Security ... and was selected to lead a national research effort to ... partner with the DHS and serve as an important team ...
... Ind. - One of the most common house ant species ... smallest spaces in a forest, but the ants have found ... Grzegorz Buczkowski, a Purdue University research assistant professor of ... more complex as they move from forest to city and ...
... their wide-view neurostimulator concept a bionic eye that ... technology. The prototype bionic eye, developed by ... and unveiled today at the BVA consortium,s official launch ... of life for patients suffering from degenerative vision loss ...
Cached Biology News:Common house ants form supercolonies, prosper in urban settings 2Bionic Vision Australia puts bionic eye in sight 2
... d1-174 GenBank Accession Number : NM_006225 ... tagged fusion protein corresponding to full length ... pH 7.4, 0.15M NaCl, 0.05% sodium azide ... Quality Assurance: routinely evaluated by immunoblot on ...
Request Info...
Request Info...
Mouse Galectin-1 Affinity Purified Polyclonal Ab...
Biology Products: